Refractory ventricular arrhythmias represent a life-threatening acutecare emergency and pose a major therapeutic challenge. Our study reports the effect of modulating cardiac sympathetic output from the neuraxis with thoracic epidural anesthesia and left cardiac sympathetic denervation for the management of refractory arrhythmias. Our observation suggests that control of serious arrhythmias can be approached in a stepwise fashion. The majority of patients presenting with malignant ventricular arrhythmias respond to a combination of ␤-blockade, antiarrhythmic drugs, and catheter ablation; however, in a subset of patients (such as the patients represented in this study), arrhythmias remain refractory. Additional therapeutic strategies such as thoracic epidural anesthesia and left cardiac sympathetic denervation could be considered in this setting. In our study, these procedures were well tolerated, without serious complications. Thoracic epidural anesthesia can be performed at the bedside; it can be used as a bridge to catheter ablation, cardiac transplantation, and left cardiac sympathetic denervation. Left cardiac sympathetic denervation can be performed in an acute setting if it is readily available when no further ablative or surgical options exist or as a bridge to nonurgent cardiac transplantation. Our findings are retrospective and will need further evaluation in prospective, randomized studies. See p 2255.
Selective Molecular Potassium Channel Blockade Prevents Atrial Fibrillation
Atrial fibrillation is the most common arrhythmia found in clinical practice, affecting 2 to 5 million people in the United States and several million more worldwide. The presence of atrial fibrillation substantially increases individual risk of stroke, heart failure, and death. A principal limitation to clinical practice is the lack of safe, effective therapies for this pervasive arrhythmia. We previously reported a gene-painting method capable of 100% transmural gene transfer to all parts of the atria accessible from an open-chest pericardium approach. In the present report, we used this method to transduce the atria with KCNH2-G628S, a mutation that blocks the rapid component of the delayed rectifier potassium current. This current is also blocked by class III antiarrhythmic drugs, but those drugs affect atrial and ventricular myocytes alike. The painting method is specific to atrial myocytes. We found that KCNH2-G628S gene transfer prolonged atrial action potential and prevented atrial fibrillation. This effect correlated with the time course of transgene expression. The method should be directly applicable to the problem of postoperative atrial fibrillation. With modifications to increase duration of gene expression and to reduce the invasive nature of delivery, the method should also be applicable to general atrial fibrillation. Formal preclinical testing is required before clinical investigation. See p 2263.
Red and Processed Meat Consumption and Risk of Incident Coronary Heart Disease, Stroke, and Diabetes Mellitus: A Systematic Review and Meta-Analysis
US dietary-guidelines recommend "eating less" red and processed meat. For cardiovascular disease, these recommendations are based largely on expected effects on blood cholesterol of saturated fat and dietary cholesterol in meats. However, relationships of meat intake with cardiometabolic disease outcomes, including coronary heart disease, stroke, and diabetes mellitus, are not well established. Additionally, few studies have separately evaluated unprocessed red versus processed meats, for which nutritional differences could produce different health effects. We systematically reviewed and pooled all available worldwide data on relationships between meat consumption and risk of coronary heart disease, stroke, or diabetes mellitus. Twenty studies were identified including 1 218 380 individuals from the United States, Europe, Australia, and Asia. When all data were pooled, consumption of unprocessed red meat (eg, unprocessed meat from beef, pork, lamb) was not associated with risk of coronary heart disease or diabetes mellitus. In contrast, each daily serving of processed meat (eg, bacon, hot dog, salami) was associated with 42% higher coronary heart disease and 19% higher diabetes mellitus risk. No associations were seen with stroke, but only 3 studies evaluated these relationships. When nationally representative US data on average types of meats consumed were analyzed, unprocessed red and processed meats contained relatively similar saturated fat and dietary cholesterol; processed meats contained much higher salt and nitrate preservatives. Our findings suggest that unprocessed red and processed meats have differing relationships with cardiometabolic outcomes and also suggest that differences in preservative contents, rather than fats, could at least partly account for these findings. Future research should separately consider potential health effects and underlying mechanisms of unprocessed versus processed meats, and current clinical and policy efforts should especially focus on reducing processed meat consumption. See p 2271.
PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A 2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry
Lipoprotein-associated phospholipase A 2 (Lp-PLA2) is transported in the circulation on high-density lipoprotein and low-density lipoprotein cholesterol particles and is present in atheromatous plaques, where it may exert proatherogenic effects through generation of lysophosphatidylcholine and oxidized fatty acids. Higher Lp-PLA2 activity is associated with increased risk of coronary heart disease (CHD) in observational studies, making Lp-PLA2 a potential therapeutic target. However, higher Lp-PLA2 activity may simply mark alterations in blood lipids and other CHD risk factors, reflect (rather than contribute to) plaque, or even play an antiatherogenic role through the hydrolysis of the proinflammatory mediator platelet-activating factor and its analogues formed on oxidation of low-density lipoprotein cholesterol. We identified common variants of the PLA2G7 gene that encodes Lp-PLA2 associated with Lp-PLA2 activity and used these to clarify the nature of the association of Lp-PLA2 with other putative risk factors and CHD events using mendelian randomization. Genetic variants associated with modest effects on Lp-PLA2 activity were not associated with major alterations in cardiovascular risk factors, coronary atheroma, or CHD events. Larger mendelian randomization analyses, perhaps with the use of variants associated with larger effects on Lp-PLA2 activity, and randomized trials of specific Lp-PLA2 inhibitors will be needed to confirm or refute a contributory role for Lp-PLA2 in CHD. See p 2284.
